2402-24-6

Usage

Uses

Used in Pharmaceutical Industry:
(3α,5β)-Tetrahydro 11-Deoxycorticosterone 21-Acetate is used as an intermediate in the synthesis of steroidal compounds for the pharmaceutical industry. Its role in potentiating GABA-receptor-mediated Cluptake makes it a valuable component in the development of drugs targeting the central nervous system, particularly those related to anxiety, epilepsy, and other neurological disorders.
Used in Research Applications:
In the field of scientific research, (3α,5β)-Tetrahydro 11-Deoxycorticosterone 21-Acetate serves as a crucial compound for studying the effects of steroids on GABA receptors and their role in neuronal function. This helps researchers better understand the mechanisms underlying various neurological conditions and develop more effective treatments.

Upstream product

• 2402-25-7 21-acetoxy-5β-pregnane-3,20-dione 
• 4469-03-8 3α-hydroxy-5β-pregnan-20-one 
• 18000-94-7 3α-formyloxy-5β-pregnan-20-one 
• 64-19-7 acetic acid 
• 96553-93-4 21-acetoxy-3α-formyloxy-5β-pregnan-20-one 
• 566-78-9 21-acetoxypregnenolone 
• 516-55-2 isopregnanolone 
• 546-67-8 lead(IV) tetraacetate 

Downstream Products

• 2402-25-7 21-acetoxy-5β-pregnane-3,20-dione 
• 567-03-3 tetrahydrodeoxycorticosterone 
• 567-02-2 (3β,5α)-3,21-dihydroxypregnan-20-one 
• 4131-27-5 21-acetoxy-3β-(toluene-4-sulfonyloxy)-5α-pregnan-20-one 
• 40129-02-0 3β,21-diacetoxy-5α-pregnan-20-one 

Relevant academic research and scientific papers

INHIBITORS OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE FOR TREATING CARDIOVASCULAR AND PULMONARY CONDITIONS

The present disclosure provides for methods of treating or preventing a cardiovascular disorder and/or a related pulmonary disorder in a subject. In certain embodiments, the method comprises administering a therapeutically effective amount of an inhibitor of Glucose-6-phosphate dehydrogenase (G6PD), or a pharmaceutically acceptable salt, non-salt amorphous form, solvate, poly-morph, tautomer or prodrug thereof.

Novel steroid inhibitors of glucose 6-phosphate dehydrogenase

Novel derivatives of the steroid DHEA 1, a known uncompetitive inhibitor of G6PD, were designed, synthesized, and tested for their ability to inhibit this dehydrogenase enzyme. Several compounds with approximately 10-fold improved potency in an enzyme assay were identified, and this improved activity translated to efficacy in a cellular assay. The SAR for steroid inhibition of G6PD has been substantially developed; the 3β-alcohol can be replaced with 3β-H-bond donors such as sulfamide, sulfonamide, urea, and carbamate. Improved potency was achieved by replacing the androstane nucleus with a pregnane nucleus, provided a ketone at C-20 is present. For pregnan-20-ones incorporation of a 21-hydroxyl group is often beneficial. The novel compounds generally have good physicochemical properties and satisfactory in vitro DMPK parameters. These derivatives may be useful for examining the role of G6PD inhibition in cells and will assist the future design of more potent steroid inhibitors with potential therapeutic utility.

METHODS, COMPOSITIONS, AND COMPOUNDS FOR ALLOSTERIC MODULATION OF THE GABA RECEPTOR BY MEMBERS OF THE ANDROSTANE AND PREGNANE SERIES

Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, insomnia and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-aminobutyric acid receptor-chloride ionophore (GR) complex.